Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:KLTO NYSE:NKGN NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.86+6.9%$2.14$1.63▼$4.66$9.58M0.81641,503 shs167,032 shsKLTOKlotho Neurosciences$0.79-1.6%$1.21$0.11▼$3.91$37.18M10.91.85 million shs1.08 million shsNKGNNKGen Biotech$0.14-17.6%$0.24$0.10▼$0.96$6.29M1.191.66 million shs971 shsPRPHProPhase Labs$0.33-7.5%$0.37$0.22▼$3.00$14.71M-0.4814.72 million shs12.65 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+3.57%-3.87%-27.20%-37.18%-31.23%KLTOKlotho Neurosciences-2.97%-17.62%-37.90%+179.15%+80,729,900.00%NKGNNKGen Biotech0.00%-17.65%-53.35%-61.11%-85.42%PRPHProPhase Labs+25.67%+15.08%-16.41%-3.80%-86.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.1772 of 5 stars3.83.00.00.02.52.50.6KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ANKGNNKGen Biotech0.4003 of 5 stars0.03.00.00.00.82.50.0PRPHProPhase Labs0.9886 of 5 stars0.05.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,244.09% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardiaN/AN/AN/AN/A($0.33) per shareN/AKLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APRPHProPhase Labs$6.77M2.01N/AN/A$0.25 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%N/AKLTOKlotho Neurosciences-$6.15M-$0.36N/A∞N/AN/A-1,779.01%-275.01%8/18/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)Latest KLTO, BCDA, PRPH, and NKGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 millionN/A8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/A5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.330.36KLTOKlotho NeurosciencesN/A0.290.29NKGNNKGen BiotechN/A0.020.02PRPHProPhase Labs0.301.030.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%KLTOKlotho Neurosciences20.07%NKGNNKGen Biotech76.17%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%KLTOKlotho Neurosciences26.70%NKGNNKGen Biotech10.36%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.50 million4.40 millionOptionableKLTOKlotho NeurosciencesN/A46.05 million33.76 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableKLTO, BCDA, PRPH, and NKGN HeadlinesRecent News About These CompaniesProPhase Labs Posts Narrower Q2 LossAugust 13 at 11:57 AM | aol.comAProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025August 13 at 8:00 AM | globenewswire.comProPhase Labs stock soars after securing patent for esophageal disease testAugust 12 at 9:20 PM | investing.comEarnings Preview For ProPhase LabsAugust 12 at 9:20 PM | benzinga.comProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease TestAugust 12 at 9:20 PM | msn.comWhy Is ProPhase Labs Stock (PRPH) Up 25% Today?August 12 at 9:20 PM | msn.comProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk AssessmentAugust 12 at 8:00 AM | globenewswire.comProPhase Labs (PRPH) to Release Quarterly Earnings on WednesdayAugust 12 at 2:51 AM | americanbankingnews.comProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025August 11 at 8:00 AM | globenewswire.comProPhase Labs Appoints New Fractional CFOAugust 6, 2025 | tipranks.comProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy StatementJuly 29, 2025 | globenewswire.comProPhase Labs announces closing of $3M senior secured convertible notesJuly 25, 2025 | msn.comProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes FinancingJuly 23, 2025 | globenewswire.comProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury InitiativeJuly 21, 2025 | globenewswire.comProPhase Labs Regains Nasdaq Compliance with New AppointmentJuly 1, 2025 | tipranks.comProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - MorningstarJune 27, 2025 | morningstar.comMProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price ComplianceJune 26, 2025 | quiverquant.comQProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleJune 26, 2025 | globenewswire.comProphase Labs Appoints Carolina Abenante as DirectorJune 25, 2025 | tipranks.comProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal CancerJune 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLTO, BCDA, PRPH, and NKGN Company DescriptionsBioCardia NASDAQ:BCDA$1.86 +0.12 (+6.90%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.08%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Klotho Neurosciences NASDAQ:KLTO$0.79 -0.01 (-1.64%) As of 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.NKGen Biotech NYSE:NKGN$0.14 -0.03 (-17.65%) As of 02:06 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.ProPhase Labs NASDAQ:PRPH$0.33 -0.03 (-7.51%) Closing price 04:00 PM EasternExtended Trading$0.32 -0.01 (-1.95%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access